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ABSTRACT
A highly sensitive and accurate liquid chromatography/mass/mass spectrometry (LC/MS/MS) system was developed to determine
the plasma concentration of procaterol in human subjects.  The chromatographic system used for this study included a Lichrospher®
Silica column with a mobile phase of 10 mM ammonium acetate aqueous solution/acetonitrile (30/70, v/v) and 1.0 mL/min flow-rate.
Procaterol and betaxolol, the latter used as the internal standard, were detected using mass spectrometry at ionization mode (ESI+), a
source block temperature of 90°C and desolvation temperature of 500°C.  The detection mass was 290.99 > 273.64 for procaterol and
308.33 > 116.31 for betaxolol.  The calibration curve over a concentration range of 0.005~1.0 ng/mL showed good linearity, with a
correlation coefficient of 0.9998.  The results of within-run and between-run precision tests for the method have coefficient variation
values of no more than 10.2%.  The average recovery rates of procaterol in human plasma samples over a wide range of concentrations
exceeded 86%.  The concentration detection and quantitation limits of the proposed LC/MS/MS method were determined to be 0.001
and 0.005 ng/mL, respectively.  The pharmacokinetic parameters from volunteers were similar to that previously reported in the literature in a study on patients administered with the same procaterol HCl dose.  All results indicate that the LC/MS/MS method proposed
in this study is a sensitive, selective, precise, and accurate method to determine concentrations of procaterol in human plasma and
hence to evaluate the pharmacokinetic characteristics of human subjects.
Key words: procaterol, LC/MS/MS assay method, pharmacokinetics

INTRODUCTION
Procaterol hydrochloride (procaterol HCl: (±)-erythro8-hydroxy-5-[1-hydroxy-2-(isopropylamino)butyl]
carbostyril hydrochloride) is a potent sympathomimetic
amine with selective beta-2 adrenergic receptor agonist
activity used in the treatment of reversible bronchospastic
diseases(1-3).  Therapeutic dose regimens for procaterol are
smaller relative to all other beta-2 adrenergic agonists (e.g.,
salbutamol, fenoterol and terbutaline(2-4)).   For example,
procaterol HCl is administered in microgram doses to treat
asthma, i.e., 10~25 µg daily for children and 50~100 µg
daily for adults(5,6).
Because it is administered in such minute dosages, the
concentration of procaterol in plasma and urine should, in
almost all circumstances, fall below the minimum level of
UV spectrophotometer sensitivity.   Referenced methods
currently used to determine the concentration of procaterol
in human or animal subject samples include radiochemical
(C14-procaterol)(7), gas chromatography-mass spectrometry
(GC/MS) (4,8), high performance liquid chromatography
(HPLC) (9), and radioimmunoassay (10,11).  The detection
limits from these methods vary widely (30 ng/mL(7), 5 ng/
mL(4), 0.010 ng/mL(8), 4.3 ng/mL(9), and 0.015 ng/mL(10),
respectively, for the above mentioned tests).   Of these,
only the gas chromatography-mass spectrometry method
developed by Huang et al.(8) and the radioimmunoassay
* Author for correspondence. Tel: +886-2-23123456 ext. 8395;
Fax: +886-2-23416347; E-mail: csg@ntu.edu.tw

method developed by Eldon et al. (10) have proven able
to detect procaterol in human plasma in a concentration
range of 0.015~2 ng/mL after oral administration of
75 µg procaterol HCl.   Other methods are unable to
detect procaterol even at maximum plasma concentrations
(Cmax) of around 0.23 ng/mL, as reported in literature(10).  
However, radioimmunoassay method experimental
procedures in most conditions are quite complicated.  
Plasma samples must be incubated with fixed amounts of
antibody and 125I-labeled procaterol, after which antibody
bound fractions must be precipitated with sheep antirabbit immunoglobulin and then counted in a gamma
counter.  Difficult disposal of isotope waste, complicated
procedures, and sophisticated instrumentation and
working environments limit the applicability of current
testing methodologies in a general chemical laboratory.  
Therefore, in this study, a novel method using a sensitive
and specific LC/MS/MS system for routine analysis of
procaterol in human plasma was developed and validated.  
This LC/MS/MS system was also applied in a preliminary
pharmacokinetics clinical trial to assess its feasibility in
human studies.

MATERIALS AND METHODS
I. Chemicals and Reagents
Procaterol HCl hemihydrate (lot no. 8611, purity
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100.4%) obtained from Edmond Pharma s.r.l. (Milano,
Italy) was used as a standard.  Betaxolol HCl (lot no. 214,
purity 100.3%) purchased from Sigma, Inc. (Steinheim,
Germany) was used as the internal standard. Procaterol
HCl pellet capsules (lot no. 212) 25 µg/cap were
manufactured by U-Chu Pharmaceutical Co., Ltd.; and
Meptin®-mini tablets 25 µg/tab (lot no. 1K84) made by
Otsuka Pharmaceutical Co., Ltd. were purchased from the
market.  Acetonitrile of HPLC-grade was purchased from
Merck KGaA (Darmstadt, Germany).  Ammonium acetate,
formic acid, di-potassium hydrogen phosphate, 2-propanol
and hydrochloric acid were the products of Sigma, Inc.
(Steinheim, Germany).
II. Liquid Chromatography/Mass/Mass Spectrometry System
The LC/MS/MS system used in this study comprised a
Liquid Chromatograph system (Waters® 1795 Separations
Module, Waters, USA), a Mass Selective Detector (Quattro
Ultima, Micromass, USA), and a Lichrospher ® Silica
column (125 mm × 4.6 mm I.D., 5 µm, E. Merck Darmstadt,
Germany) thermostated at 40°C  by a column heater.  
The mobile phase was composed of 10 mM ammonium
acetate aqueous solution and acetonitrile (30:70, v/v) eluted
with a flow-rate of 1.0 mL/min. The injection volume was
15 µL, and post column split 1/10 to Mass Selective
Detector and 9/10 to waste.  The Mass Selective Detector
was set as follows: ionization mode (ESI+), ESI voltage
3.0 kV, source block temperature 90°C, desolvation
temperature 500°C, and detection mass for procaterol (MW
290.36 g/mol) parent ion at m/z 290.99 > fragment ion at m/
z 273.64 and for betaxolol (MW 307.43 g/mol) parent ion at
m/z 308.33 > fragment ion at m/z 116.31.
(I) Stock and Working Solutions
Stock solutions of both procaterol HCl and betaxolol
HCl (internal standard) of 1000 µg/mL in 50% acetonitrile
solution were prepared and stored at 4°C.  The working
solutions of procaterol HCl and betaxolol HCl in blank
plasma, obtained from healthy adult volunteers, were freshly
prepared with procaterol HCl concentrations of 0.001, 0.01,
0.1, 1.0, and 10.0 µg/mL, respectively, and a betaxolol HCl
concentration of 0.02 µg/mL.
(II) The Stability Studies of Procaterol HCl in Human
Plasma
Studies of freeze-thaw stability as well as short-term
and long-term stability were conducted to confirm the
stability of procaterol in plasma.   Samples of procaterol
HCl in drug-free human plasma in two concentrations (0.015
ng/mL and 0.8 ng/mL) were prepared and used for a freezethaw stability study that included three cycles and six
replicates.
Samples of procaterol HCl in drug-free human plasma
in four concentration levels (0.005, 0.015, 0.08 and 0.8

ng/mL) were used to assess both short-term and long-term
stability after one freeze-thaw cycle.  The short-term study
was carried out at 0, 2, and 4 hr after thawing the sample
with no further preparation.   For the long-term study,
samples were examined at 0 and 24 hr following thawing
and further preparation (in accordance with preparation
procedures for pharmacokinetic study samples).
(III) Validation Studies
For validation studies, a series of standard solutions
of procaterol HCl in 0.5 mL of drug-free human plasma in
concentrations of 0.005, 0.01, 0.02, 0.05, 0.1, 0.2, 0.5 and
1.0 ng/mL were freshly prepared.  The plasma sample was
mixed with a 5-µL internal standard working solution (0.02
µg/mL betaxolol HCl) and 25 µL 1 M K2PO4 solution, and
then extracted with 5.0 mL of 2-propanol and vortexed
for 2 min.  After centrifugation at 3000 rpm for 10 min,
the supernatant layer was transfer into a conical tube.  A
solution of 100 µL of 3% formic acid was added to the
conical tube and mixed by vortexing for 30 sec.   The
sample was centrifuged again at 3000 rpm for 10 min, and
the organic layer was removed.  The aqueous solution was
evaporated to dryness under a stream of nitrogen gas for
5 min at ambient condition.  The residues were dissolved
in 200 µL of acetonitrile and vortex-mixed for 1 min.  We
then transferred 150 µL of the solution to a sample vial.
A volume of 15 µL was then injected into the LC/MS/MS
system.  A calibration curve was established by plotting
the peak area ratio, i.e., peak area of procaterol over
peak area of betaxolol, as a function of procaterol HCl
concentration. Recovery, within-run, and between-run tests
were conducted to ensure the reliability of our proposed
method.  The sample concentrations were then calculated
by interpolating the peak area ratio for each sample into the
calibration curve.  All experiments were repeated six times.  
All data were presented as mean ± S.D.  The lowest limit
of detection was defined as a detection concentration at a
signal-to-noise ratio of 3:1.
III. A Preliminary Clinical Trial of Two Procaterol HCl
Preparations
Four healthy male Taiwanese subjects, each having
provided written informed consent, were enrolled in this
preliminary clinical trial.   The trial was designed as a
single dose, non-blinded, randomized, balanced, twosequence, and two-period crossover study.  Before the trial,
the physical and biochemical condition of each volunteer
was examined. Subjects were aged between 20 and 25
years (22.8 ± 2.2 years), weighed between 57.4 and 75.6
kg (65.0 ± 7.8 kg), and ranged from 167.4 to 177.3 cm in
height (171.0 ± 4.4 cm).   Each healthy subject received
either three procaterol HCl pellet capsules (25 µg/capsule)
or three Meptin®-mini tablets (25 µg/tablet), administered
orally with 200 mL of water.  A washout period of 7 days
was maintained between the two administrations.  Prior to
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administering each dose, a 20 mL sample of blood from
each subject was taken as blank, and a 10 mL sample of
blood was drawn at 0.33, 0.67, 1, 1.67, 2, 2.5, 3, 4, 6, 8, 10,
12, 14 and 16 hr after dose administration.  Blood samples
were collected from the antecubital vein using coded
vacutainers and were centrifuged immediately at 3000 rpm,

4°C for 10 min using a Kubota® KN-70 (Double Enterprise
Co., Ltd., Japan).  The plasma layer was then transferred to
a labeled test tube and stored at -20°C until analysis.  The
plasma concentrations of procaterol were then assayed in
accordance with our proposed LC/MS/MS method.
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Figure 1. Mass spectra of standards of (A) procaterol and (B) betaxolol.
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(I) Sample Preparation
A plasma sample of 0.5 mL was pipetted accurately
and mixed with 5 µL of internal standard working solution
(betaxolol, 0.02 µg/mL).   The remaining preparation
procedures were similar to those described in the section on
validation studies.  Following preparation, 15 µL of sample
solution was injected into the LC/MS/MS system.
(II) Pharmacokinetic Analysis
Area under the curve (AUC), maximum plasma
concentration (C max ), time at maximum concentration
100

(T max ), mean residence time (MRT), and elimination
half life (t 1/2) were determined from procaterol plasma
co ncen tr atio n - time p ro f iles u s in g meth od o lo gies
recommended by Gibaldi(12).
(III) Statistical Treatments
The log-transformed data (geometric means) of
AUC 0→16 , AUC 0→∞ , and C max and the MRT data with
sequence, period, and treatment effects were analyzed using
an analysis of variance (ANOVA) model by the Statistical
Analysis System (SAS) GLM Procedure, version 8.1.
Differences in data set values of p < 0.05 were considered
statistically significant.

(A) Blank plasma
308.06 > 116.12
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Figure 2. Chromatograms after mass selective ion detector for (A)
blank plasma, (B) plasma with betaxolol and procaterol (0.005 ng/
mL), (C) plasma from volunteer who took procaterol 75 µg HCl (1
hr later). The base peaks of procaterol and betaxolol were revealed at
m/z 273.64 and 116.31, respectively.

Figure 1A depicts the procaterol HCl standard mass
spectra (MW 290.36 g/mol), with a base peak at m/z 273.64
from the parent fragment at m/z 290.99.  In Figure 1B, the
mass spectra of internal standard betaxolol (MW 307.43
g/mol) shows a base peak at m/z 116.31 from the parent
fragment at m/z 308.33.   In order to check for possible
distortions due to the methodology used to assay material
extracted from plasma samples we employed an LC/MS/
MS system to analyze the samples of blank plasma from
volunteers; plasma mixed with betaxolol and procaterol
at the lowest concentration (0.005 ng/mL), i.e., used for
the standard solution series, and volunteer plasma samples
that had been treated with 75 µg procaterol hydrochloride
mixed with betaxolol.  The resultant chromatograms are
presented in Figures 2A, 2B, and 2C, respectively.  While
no significant peak appears in Figure 2A, the procaterol
and betaxolol peaks in Figures 2B and 2C chromatograms
are sharp and symmetrical, with high resolution and with
the retention times of approximately 2.3 min and 4.0
min, respectively.  The procaterol retention time for the
proposed system is much shorter than that previously
reported data (e.g., 5.0 min by Ishigami et al.(4), 15.1 min
by Hunag et al.(8) and 16.5 min by Wright et al.(9)).  The
fact that no endogenous interfering peak appeared in our
chromatograms suggests that the developed LC/MS/MS
assay system is valid.
II. Validation of the Assay Method
Table 1 shows the results of stability studies on
procaterol HCl in plasma.  Differences in the determined
concentration of procaterol HCl between samples at time
0 and samples after the first, second and third freeze-thaw
cycles, respectively, were all within 3%.   Determined
concentration differences of procaterol HCl between time
0 and at the times monitored for short-term and longterm stability were all within 5%.   Results indicated that
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Table 1. The data of the stability studies of procaterol HCl in human plasma
Spike concentration (ng/mL)

0.005

0.015

Freeze-thaw stability
Measured
Initial
—
0.0155 ± 0.0007
concentrationa (ng/mL) 1st cycle
—
0.0151 ± 0.0008 (-2.58)
(% difference to initial) 2nd cycle
—
0.0154 ± 0.0010 (-0.65)
3rd cycle
—
0.0155 ± 0.0007 (0.0)
Short-term stability
Measured
0 hr
0.048 ± 0.0003
0.0152 ± 0.0002
concentrationa (ng/mL) 2 hr
0.0050 ± 0.0005 (4.57)
0.0150 ± 0.0002 (-1.10)
(% difference to initial) 4 hr
0.0051 ± 0.0006 (4.98)
0.0149 ± 0.0003 (-1.76)
Long-term stability
Measured
0 hr
concentrationa (ng/mL) 24 hr
0.0057 ± 0.0001
0.00151 ± 0.0040
(% difference to initial)
0.0055 ± 0.0002 (-3.51) 0.0150 ± 0.0003 (-0.66)
a
All the data are mean ± S.D. (n = 6).

Table 2. Recovery rate of procaterol and betaxolol in plasma of healthy human subjectsa
Concentration (ng/mL)
Peak area of procaterol
Peak area of betaxolol
0.005
0.01
0.02
0.05
0.1
0.2
0.5
1.0

66.51 ± 3.85
147.51 ± 4.32
170.83 ± 6.85
436.39 ± 13.85
870.57 ± 24.92
1407.29 ± 35.48
3143.74 ± 124.67
7279.02 ± 208.92

3134.59 ± 110.81
4018.57 ± 128.33
3031.89 ± 123.73
3721.51 ± 101.71
3207.55 ± 103.08
2789.05 ± 120.42
2625.79 ± 123.04
2992.92 ± 136.36

0.08
—
—
—
—

0.8
0.7871 ± 0.0650
0.7702 ± 0.0481 (-2.15)
0.7911 ± 0.0501 (0.50)
0.7823 ± 0.0404 (-0.61)

0.0794 ± 0.0006
0.8137 ± 0.0070
0.0795 ± 0.0015 (0.21) 0.8110 ± 0.0046 (-0.33)
0.0789 ± 0.0021 (-0.58) 0.8107 ± 0.0085 (-0.37)
0.0815 ± 0.0013
0.8142 ± 0.0060
0.0811 ± 0.0009 (-0.49) 0.8143 ± 0.0049 (0.01)

Peak area ratio

Recovery (%)

0.021 ± 0.001
0.037 ± 0.002
0.056 ± 0.005
0.117 ± 0.007
0.271 ± 0.015
0.505 ± 0.035
1.197 ± 0.103
2.432 ± 0.101

86.15 ± 4.86
109.34 ± 8.51
94.02 ± 9.98
88.14 ± 6.03
107.85 ± 6.29
102.38 ± 7.19
98.28 ± 8.49
100.29 ± 4.18

a

Mean ± S.D. of six repeated experiments.

Table 3. Results of within-run and between-run tests
Spiked concentration (ng/mL)
0.005
0.01
0.02
0.05
0.1
0.2
0.5
1.0

Within-run test
a

Between-run test

Measured conc. (ng/mL)

S.D.

CV (%)

Measured conc.a (ng/mL)

S.D.

CV (%)

0.0051
0.0099
0.0197
0.0506
0.0992
0.205
0.483
1.01

0.0002
0.0009
0.0020
0.0030
0.0063
0.014
0.042
0.04

4.7
8.6
10.2
5.9
6.4
6.8
8.7
4.0

0.0054
0.0105
0.0195
0.0459
0.102
0.194
0.484
1.03

0.0004
0.0007
0.0017
0.0023
0.008
0.011
0.025
0.02

8.0
6.7
8.7
5.0
7.8
5.7
5.2
1.9

a

Mean of six repeated experiments in six days.

procaterol in human plasma exhibits good stability at the
experimental conditions employed for this study.
The calibration curve for the ratio of peak
area response (procaterol/betaxolol) vs. that for the
concentration of procaterol HCl standard solutions analyzed
by our proposed LC/MS/MS system demonstrated a linear
relationship over a concentration range of 0.005~1.0
ng/mL, with a regression line of y = 2.414x + 0.0106
and a correlation coefficient of r2 = 0.9998.  Table 2 lists
the results of the recovery test for procaterol in plasma
solutions over the same concentration range.  The average
recovery rate (n = 6) for each solution ranged from 86.15%
to 109.34%, which was considered acceptable.  Table 3
summarizes the results of within-run and between-run tests

for eight procaterol in plasma standard solutions, presented
in standard deviation (S.D.) and coefficient of variance
(C.V.) formats.  All data are derived from the results of
six repeated experiments performed on each concentration
over three separate days. C.V. values ranged from 4.0% to
10.2% for the within-run test and from 1.9 % to 8.7% for
the between-run test.  The above results indicate that the
proposed assay method is quite reliable.
Detection limit and quantitation limit concentrations
for the proposed LC/MS/MS method were identified as
0.001 and 0.005 ng/mL, respectively.  The detection limit
concentration in this method is below the lowest detectable
values of 0.010 ng/mL using the GC/MS method(8) and
0.015 ng/mL using the radioimmuno-assay method (10) .  
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Table 4. The pharmacokinetic parameters of procaterol HCl pellets capsules and Meptin®-mini tablets after oral administration to healthy male
adults (Mean ± S.D., n = 4)
Parameters

Procaterol HCl pellets capsule

Meptin®-mini tablet

ANOVA p-valuea

0.906 ± 0.334
1.03 ± 0.37
87.6 ± 3.1
0.211 ± 0.078
7.36 ± 0.98
1.00 ± 0.27
5.90 ± 0.72

0.870 ± 0.216
0.932 ± 0.214
93.0 ± 2.4
0.219 ± 0.091
5.76 ± 1.12
0.835 ± 0.191
4.63 ± 1.05

0.269
0.583

AUC0→16 (hr • ng/mL)
AUC0→∞ (hr • ng/mL)
AUC0→16/ AUC0→∞ (%)
Cmax (ng/mL)
MRT (hr)
Tmax (hr)
T1/2(hr)
a

0.950
0.128
0.176
0.122

p < 0.05 as the breaking point for statistical significant difference.

to results reported in the literature on an experiment with
patients treated with the same procaterol HCl dose (10),
where AUC0→∞ was 1.380 ± 0.286 hr • ng/mL, Cmax was
0.233 ± 0.299 ng/mL, T max was 0.835 ± 0.191 hr, and
T1/2 was 2.0 ± 0.55 hr.  These results demonstrate that the
LC/MS/MS method developed here is suitable for use in
pharmacokinetic studies to detect procaterol at very low
plasma concentrations.

Plasma concentration (ng/mL)

0.35
0.30
Meptin-mini tablets
Procaterol HCl pellets capsules

0.25
0.20
0.15
0.10

CONCLUSIONS

0.05
0.00

0

5

10

15

20

Time (hr)

Figure 3. Mean plasma procaterol concentration vs. time for
healthy adult subjects (n = 4) after single dose oral administration of
procaterol HCl pellets capsules (–○–) and Meptin®-mini tablets (–●–).

In other words, the sensitivity achieved by the proposed
LC/MS/MS method is greater than that of other reported
methods.   Other advantages of the proposed LC/MS/MS
method include the absence of isotope waste handling
issues, easy operations and relative simple experimental
procedures, and reduced processing times.
III. Application to a Preliminary Human Study
We applied the proposed LC/MS/MS system on
samples from healthy adult human subjects to determine
procaterol plasma concentrations.  The resultant kinetics
curves representing mean drug plasma concentration
versus time after oral administration of two procaterol HCl
preparations are depicted in Figure 3.  The two curves are
almost superimposed on each other.  The proposed LC/
MS/MS method was able to detect procaterol in a plasma
concentration range of 0.005~1.0 ng/mL.  The calculated
pharmacokinetic parameters for each group are summarized
in Table 4 as mean ± S.D.  Table 4 lists the p-values of each
parameter for both formulations. There was no significant
difference (p > 0.05) between the two treatment groups
in terms of pharmacokinetic parameters (e.g., AUC0→16,
AUC0→∞, Cmax, MRT, Tmax and T1/2).  They are similar

A sensitive LC/MS/MS system was developed to
determine the presence of plasma procaterol at extremely
low concentration levels for use in studies on human
subjects.  The data in this paper supports that the proposed
LC/MS/MS method has good selectivity, accuracy and
precision, with detection sensitivity reaching concentrations
of 0.001 ng/mL.  The LC/MS/MS system is a valid method
for use in human pharmacokinetic studies.
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